AAA
IMVT icon

Affinity Asset Advisors’s Immunovant IMVT Stock Holding History

Affinity Asset Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128,100
Closed -$4.92M – 90
2023
Q3 		$4.92M Buy
+128,100
New +$2.9M 1.38% 25

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's IMVT Position: Q2 2026 in Review

Affinity Asset Advisors held its Immunovant (IMVT) position steady in Q2 2026 at 100,000 shares worth $3.85M. The position accounts for 0.17% of the portfolio, ranked #87.

Affinity Asset Advisors first reported a position in IMVT in Q4 2020 and has held it in 13 quarters since. The position peaked at $14.5M in Q4 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Affinity Asset Advisors held 100,000 shares of Immunovant worth $3.85M as of Q2 2026.
  • Affinity Asset Advisors left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up 0.17% of Affinity Asset Advisors's portfolio in Q2 2026, its #87 holding.
  • Affinity Asset Advisors first reported a position in Immunovant in Q4 2020 and has held it in 13 quarters since.
  • Affinity Asset Advisors's Immunovant position peaked at $14.5M in Q4 2023.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.